| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGB |
| Uniprot No | P02675 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 45-491aa |
| 氨基酸序列 | GHRPLDKKREEAPSLRPAPPPISGGGYRARPAKAAATQKKVERKAPDAGGCLHADPDLGVLCPTGCQLQEALLQQERPIRNSVDELNNNVEAVSQTSSSSFQYMYLLKDLWQKRQKQVKDNENVVNEYSSELEKHQLYIDETVNSNIPTNLRVLRSILENLRSKIQKLESDVSAQMEYCRTPCTVSCNIPVVSGKECEEIIRKGGETSEMYLIQPDSSVKPYRVYCDMNTENGGWTVIQNRQDGSVDFGRKWDPYKQGFGNVATNTDGKNYCGLPGEYWLGNDKISQLTRMGPTELLIEMEDWKGDKVKAHYGGFTVQNEANKYQISVNKYRGTAGNALMDGASQLMGENRTMTIHNGMFFSTYDRDNDGWLTSDPRKQCSKEDGGGWWYNRCHAANPNGRYYWGGQYTWDMAKHGTDDGVVWMNWKGSWYSMRKMSMKIRPFFPQQ |
| 预测分子量 | 54.8kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FGB(纤维蛋白原β链)重组蛋白研究的示例参考文献(注：以下为模拟示例，非真实文献，仅供参考格式和内容)：
---
1. **文献名称**：*Expression and Functional Analysis of Recombinant Human Fibrinogen Beta Chain in E. coli*
**作者**：Smith J. et al.
**摘要**：该研究报道了通过大肠杆菌表达系统成功重组表达人源FGB蛋白，并验证其促进血小板聚集和纤维蛋白形成的功能，为开发止血材料提供基础。
2. **文献名称**：*Role of Recombinant FGB in Thrombosis: Insights from In Vitro Models*
**作者**：Chen L. et al.
**摘要**：利用重组FGB蛋白研究其在血栓形成中的作用，发现其与血管内皮细胞相互作用可增强凝血级联反应，提示其作为血栓性疾病治疗靶点的潜力。
3. **文献名称**：*Purification and Structural Characterization of Recombinant FGB for Biomedical Applications*
**作者**：Wang Y. et al.
**摘要**：通过亲和层析技术纯化重组FGB，结合质谱和X射线晶体学解析其三维结构，为设计基于FGB的仿生材料(如水凝胶)提供理论依据。
4. **文献名称**：*FGB Recombinant Protein Enhances Wound Healing in Diabetic Mice*
**作者**：Kim S. et al.
**摘要**：动物实验表明，局部应用重组FGB可加速糖尿病小鼠皮肤创面的愈合，机制可能与促进细胞迁移和血管生成相关。
---
**说明**：以上文献为模拟示例，实际研究中建议通过PubMed或Web of Science检索真实文献(关键词如"recombinant fibrinogen beta"或"FGB protein expression")。如需具体文献推荐，可进一步明确研究方向(如疾病机制、材料科学等)。
Fibrinogen beta chain (FGB) is a critical component of fibrinogen, a large glycoprotein complex essential for blood coagulation and wound healing. Naturally synthesized in the liver, fibrinogen consists of three pairs of polypeptide chains (Aα, Bβ, and γ) linked by disulfide bonds. During vascular injury, thrombin cleaves fibrinogen to form fibrin monomers, which polymerize into a clot matrix. The FGB chain plays a pivotal role in this process by contributing to fibrinopeptide B release, clot structure stability, and interactions with platelets or endothelial cells.
Recombinant FGB (rFGB) is produced using genetic engineering techniques, often in expression systems like *E. coli*, yeast, or mammalian cells. Its development addresses challenges in studying fibrinogen-related disorders (e.g., dysfibrinogenemia, thrombophilia) and provides a standardized material for research. Unlike plasma-derived fibrinogen, rFGB offers precise control over post-translational modifications, enabling studies on specific mutations or glycosylation patterns affecting clot formation. Additionally, recombinant technology minimizes risks of pathogen contamination, making it safer for therapeutic applications.
Recent advances focus on optimizing rFGB production to mimic natural isoforms and enhance functionality. Researchers also explore its potential in biomaterials (e.g., fibrin-based scaffolds for tissue engineering) and targeted drug delivery systems. However, challenges persist in replicating complex γ-chain crosslinking and achieving cost-effective large-scale production. Ongoing studies aim to refine expression systems and characterize rFGB's biophysical properties, bridging gaps between in vitro models and clinical applications in hemostasis, thrombosis, and regenerative medicine.
×
